A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...
Cells contain a blueprint in the form of DNA that dictates what they can make. This blueprint is converted into a message ...
In a 2025 qualitative analysis of payer insights conducted by McKesson and Lumanity, 20 payers representing nearly 280 million covered lives reported that although they broadly view CGTs as safe (90%) ...
With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...
Mr Andrews contacted the medical team at Mass General Hospital ( MGH), the hospital in Massachusetts that had carried out the ...
The news for the chocolate industry is a welcome development, as businesses and scientists grapple with crop shortages.
We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by ...
Cells contain a blueprint in the form of DNA that dictates what they can make.This blueprint is converted into a message, or mRNA, which is then ...
Medpage Today on MSN
ATTR Trial's Safety Freeze; Heart Failure After Twins; Sotatercept Approval Expands
As alternatives to intravascular lithotripsy, cutting balloon angioplasty and super-high-pressure non-compliant balloons were noninferior in the Short-CUT and VICTORY trials, as highlighted by the ...
Raipur: Medical experts at AIIMS Raipur have called for a comprehensive national effort to boost organ donation in India, ...
Q3 2025 Earnings Call October 28, 2025 8:30 AM EDTCompany ParticipantsJacob JohnsonOlivier Loeillot - President, ...
Clinical Trials Arena on MSN
Intellia pauses Phase III gene therapy trial after patient hospitalised
A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results